<DOC>
	<DOCNO>NCT01768559</DOCNO>
	<brief_summary>Primary Objective : - To compare lixisenatide versus insulin glulisine term glycosylated hemoglobin ( HbA1c ) reduction body weight change Week 26 type 2 diabetic participant adequately control insulin glargine ± metformin . Secondary Objectives : - To compare treatments/regimens : - The percentage participant reach target HbA1c &lt; 7 % ≤6.5 % , - Body weight , - Self-Monitored Glucose profile , - Fasting Plasma Glucose ( FPG ) , - Post-prandial plasma glucose ( PPG ) /glucose excursion standardize meal test ( subset participant ) , - Daily dos insulin , - Safety tolerability .</brief_summary>
	<brief_title>Efficacy Safety Lixisenatide Versus Insulin Glulisine Top Insulin Glargine With Without Metformin Type 2 Diabetic Patients</brief_title>
	<detailed_description>Approximately 41 week include 26 week treatment period .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Participants type 2 diabetes mellitus diagnose least 1 year screen visit ( V1 ) . Participants treat basal insulin least 6 month . Participants treat least 3 month prior visit 1 stable basal insulin regimen ( i.e . type insulin time/frequency injection ) . The insulin dose stable ( ± 20 % ) ≥20 U/day least 2 month prior visit 1 . Participants treat basal insulin alone combination 1 3 oral antidiabetic drug ( OADs ) could : metformin ( ≥1.5 g/day maximal tolerate dose ) , sulfonylurea ( SU ) , dipeptidylpeptidase4 ( DPP4 ) inhibitor , glinide . The dose OADs stable least 3 month prior visit 1 . Exclusion criterion : At screening : age &lt; legal age majority . At screening , HbA1c : &lt; 7.5 % &gt; 10.0 % participant treat basal insulin alone combination metformin ; &lt; 7.0 % &gt; 10.0 % participant treat basal insulin combination oral antidiabetic drug include SU and/or DPP4 inhibitor and/or glinide . Women childbearing potential effective contraceptive method , pregnancy lactation . Type 1 diabetes mellitus . Treatment glucoselowering agent ( ) state inclusion criterion within 3 month prior screen . Previous treatment short rapid act insulin relation hospitalization acute illness . Any previous treatment lixisenatide , discontinuation another glucagonlike peptide 1 ( GLP1 ) receptor agonist due safety/tolerability issue lack efficacy . At screen , Body Mass Index ( BMI ) ≤20 &gt; 40 kg/m^2 . Weight change 5 kg 3 month prior screen visit ; use weight loss drug within 3 month prior screen . Within last 6 month prior screen : history myocardial infarction , stroke , heart failure require hospitalization . Planned coronary , carotid peripheral artery revascularisation procedure . History unexplained pancreatitis , chronic pancreatitis , pancreatectomy , stomach/gastric surgery . At screen rest systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 95 mmHg . Personal immediate family history medullary thyroid cancer ( MTC ) genetic condition predispose MTC ( e.g . multiple endocrine neoplasia syndrome ) . Contraindication related metformin ( participant receive treatment ) , insulin glargine , insulin glulisine lixisenatide . Participants severe renal impairment ( creatinine clearance le 30 ml/min ) endstage renal disease . At screening , amylase and/or lipase &gt; 3 time upper limit normal laboratory range ( ULN ) . At screen alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 3 ULN . At screen calcitonin ≥20 pg/ml ( 5.9 pmol/L ) . Exclusion Criteria randomization end screen period randomization : HbA1c &lt; 7.0 % &gt; 9.0 % . 7day mean fast SMPG &gt; 140 mg/dl ( 7.8 mmol/L ) . Amylase and/or lipase &gt; 3 time ULN . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>